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ARTICLE
Genomic analysis of a pre-elimination Malaysian
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pressures and changing transmission dynamics
Sarah Auburn 1,2, Ernest D. Benavente 3, Olivo Miotto 2,4,5, Richard D. Pearson 2,4, Roberto Amato2,4,
Matthew J. Grigg1,6, Bridget E. Barber 1,6, Timothy William6,7,8, Irene Handayuni1, Jutta Marfurt1,
Hidayat Trimarsanto9,10, Rintis Noviyanti9, Kanlaya Sriprawat11, Francois Nosten 11,12, Susana Campino3,
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The incidence of Plasmodium vivax infection has declined markedly in Malaysia over the past
decade despite evidence of high-grade chloroquine resistance. Here we investigate the
genetic changes in a P. vivax population approaching elimination in 51 isolates from Sabah,
Malaysia and compare these with data from 104 isolates from Thailand and 104 isolates from
Indonesia. Sabah displays extensive population structure, mirroring that previously seen with
the emergence of artemisinin-resistant P. falciparum founder populations in Cambodia. Fifty-
four percent of the Sabah isolates have identical genomes, consistent with a rapid clonal
expansion. Across Sabah, there is a high prevalence of loci known to be associated with
antimalarial drug resistance. Measures of differentiation between the three countries reveal
several gene regions under putative selection in Sabah. Our ﬁndings highlight important
factors pertinent to parasite resurgence and molecular cues that can be used to monitor low-
endemic populations at the end stages of P. vivax elimination.
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Outside of sub-Saharan Africa, Plasmodium vivax hasbecome the predominant cause of malaria1. Reports ofantimalarial drug resistance and life-threatening com-
plications in children and pregnant women underline the
importance of containing this species2–6. However, whilst the
incidence of P. falciparum has declined in most endemic coun-
tries, the proportion of P. vivax infections in co-endemic regions
has demonstrated a consistent rise, highlighting the remarkable
adaptive potential and relative resilience of this species7. The re-
emergence of P. vivax in many regions following successful
elimination programmes serves as an important reminder of the
parasite’s propensity to resurge in areas where it was once almost
eliminated8. In order for malaria programmes to interrupt
transmission successfully, a relentless focus is required on sur-
veillance to identify foci of infection and instigate appropriate
control responses to eliminate these. A better understanding of
the transmission dynamics and adaptive processes of the parasite
is essential. Whilst several genomic studies have explored the
molecular dynamics of P. vivax populations with stable trans-
mission9–13, aside from a small selection of microsatellite-based
studies14–16, little is known about the molecular epidemiology
during the critical, end stages of malaria elimination.
Malaysia has experienced a sharp decline in P. vivax prevalence
over the past decade17,18, providing a unique endemic setting
from which to assess the changing transmission dynamics and
selective pressures as the parasite population enters the vulnerable
malaria pre-elimination phase. A recent clinical trial demon-
strated high-grade chloroquine resistance (CQR) with parasite
recurrence reported within 28 days of starting treatment in 60%
of patients19. Despite declining treatment efﬁcacy, the number of
reported P. vivax cases has fallen from approximately 3000 in
2005 to under 100 in 20151. Most P. vivax malaria is reported
from the island of Borneo, where control efforts are challenged by
constraints in case detection and accessibility to effective diag-
nosis and treatment. A recent microsatellite-based study of iso-
lates collected in Sabah between 2010 and 2012 demonstrated
local fragmentation and evidence of unstable transmission14.
Since then, indigenous cases of P. vivax have continued to decline,
but the threat of resurgence remains high, driven by an increase
in imported cases1, and high levels of CQR19.
To explore the critical transition to P. vivax elimination,
genome-wide population genetic analysis was undertaken on
clinical isolates from Sabah, Malaysia and compared with isolates
from western Thailand and Indonesia. In Thailand, P. vivax
transmission is falling and 5 to 15% of patients treated with CQ
have recurrent parasitaemia by day 28 (low-grade CQR)20. In
Papua, Indonesia P. vivax transmission remains high and stable,
with more than 50% of patients treated with CQ having recurrent
parasitaemia by day 28 (high-grade CQR)21. The parasite popu-
lation structure in Sabah was examined for evidence of unstable
transmission and bottlenecking, and comparative analyses were
undertaken against Thailand and Indonesia to identify genomic
regions under putative selection. Further investigation of the
temporal dynamics and epidemiological risk factors of speciﬁc
parasite strains were investigated in a broader selection of sam-
ples using new and published microsatellite data14 on isolates
collected between 2010 and 2015.
Our results reveal that the P. vivax population in Sabah is
highly structured with high relatedness amongst infections,
declining diversity and increased inbreeding, consistent with
declining but also increasingly unstable transmission. A large
clonal expansion is observed, potentially reﬂecting the emergence
of an adaptive new strain. A high prevalence of known resistance
determinants is observed in Sabah, and several new signals of
selection have been revealed, requiring further investigation with
clinical phenotypes. These ﬁndings highlight the substantial
adaptive potential in a pre-elimination P. vivax population, and
the need for a stronger framework for molecular surveillance to
track the early emergence of adaptive new strains.
Results
Genomic data summary. A total of 259 independent samples had
high-quality genomic data, with <5% missing genotype calls at
527,107 high-quality typeable single-nucleotide polymorphisms
(SNPs). Corresponding genotype failure rates were below 5%. The
high-quality samples included 51 isolates from Sabah collected
between May 2011 and December 2014; 3 (5.9%) of which came
from the West Coast, with the remaining 48 (94.1%) from Kudat
Division. Additional high-quality samples were available from
Thailand (n= 104) and Indonesia (n= 104).
Low complexity of infection in Sabah. Within-sample parasite
diversity was characterised using FWS analysis, and revealed a
signiﬁcantly higher proportion of monoclonal infections in Sabah
(84.3%, 43/51) relative to Thailand (65.4%, 68/104) and Papua
Indonesia (51.9%, 54/104) (Pearson’s χ2 test, p= 0.0234; p=
1.8 × 10−4), indicative of less frequent superinfection and/or co-
transmission (Fig. 1). Individual FWS scores are presented in
Supplementary Data 1.
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Fig. 1 FWS plots illustrating trends in within-sample infection complexity in Sabah Malaysia, Thailand and Indonesia. Boxplots (a) and scatter plots (b) of the
FWS measure, which provides a gauge of the diversity within individual infections scaled from 0 (high diversity) to 1 (no diversity). The boxplot boxes
present the median and interquartile range, with the lower whiskers presenting max(min(x), quartile 1–1.5 × interquartile range). The dotted line in (b)
illustrates the FWS= 0.95, above which infections are essentially monoclonal. A higher proportion of monoclonal infections are observed in Sabah,
Malaysia, relative to Thailand and Indonesia. The plots were generated using genomic data on 259 high-quality samples
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Marked population structure in Sabah. At the population-level,
principal coordinate analysis (PCoA) illustrated that, other than
three putative imported cases, the isolates from Sabah were
genetically distinct from Thailand and Indonesia, and exhibited
striking population structure (Fig. 2a, b). Extensive population
structure was observed in Sabah, in marked contrast to Thailand
and Indonesia, which displayed tight clusters with no evidence of
structure. Whilst the ﬁrst principal component (PC1) separated
Thailand and Indonesia, located over 4500 km apart, PC2 was
driven by the variation within Sabah, where the maximal geo-
graphic distance between sites was <200 km. ADMIXTURE
analysis conﬁrmed the separation between countries and distinct
structure within Sabah, identifying four sub-populations in the
country-wide sample set (Supplementary Fig. 2). In accordance
with the PCoA plots, Thailand and Indonesia formed two distinct
sub-populations (K1 and K4), while Sabah was split into two
major sub-populations, K2 (n= 26, 51%) and K3 (n= 17, 33%),
as well as a subset of admixed samples with <70% ancestry to any
given K (n= 5, 10%), and 3 (6%) cases deﬁned as putatively
imported on the basis of ancestry ranging from 80 to 100% to K1
or K4 (Fig. 2c). Whilst the K2 sub-population was clearly
diverged, there was also extensive divergence among the K3 and
mixed infections. Despite the K2 and K3 isolates being derived
from the same Division in Sabah (Kudat), the genetic divergence
between these sub-populations (FST= 0.479) was greater than
that observed between K1 and K4 (FST= 0.295).
Genetically identical K2 infections. Neighbour-joining analysis
conﬁrmed the extensive structure within Sabah, illustrating
clusters of highly related infections, in marked contrast to more
panmictic structure in Thailand and Indonesia (Fig. 3). Strikingly,
all 26 K2 infections were genetically near-identical (Fig. 3). The
median difference between pairs of K2 isolates across the 527,107
SNPs was ﬁve nucleotides (i.e. differing at 0.0009% SNPs on
average). After excluding the imported isolates and using a single
representative of the K2 strain, the median SNP-based nucleotide
difference across Sabah was 11,333 (2.15% SNPs), demonstrating
a moderately diverse underlying reservoir of infection despite the
high prevalence of identical isolates. Higher levels of pairwise
nucleotide divergence were observed in Thailand (15,433
nucleotide differences, 2.93% SNPs) and Indonesia (13,423
nucleotide differences, 2.55% SNPs).
Large region of sequence homology in Sabah. To explore the
chromosome-level structure in the Sabah isolates, patterns of
identity by descent (IBD) were explored across the genome of
Sabah (both with all isolates and with a single K2 representative),
Thailand and Indonesia (Supplementary Data 2). Sabah exhibited
higher fractions of pairwise IBD across the genome (median=
0.446, range 0.061–0.768) than Thailand (median= 0.012, range
0.004–0.221) and Indonesia (median= 0.022, range 0.001–0.273)
(Wilcoxon's rank-sum test, both p < 2.2 × 10−16) reﬂecting higher
relatedness. Levels of pairwise IBD were further lower in the
baseline Sabah population, where the K2 strain was represented
once (median= 0.267, range 0.133–0.642). Illustrations of the
IBD along each chromosome are presented in Supplementary
Fig. 3. The top 5% IBD positions in Malaysia (all or baseline
samples) were distributed across 10 regions on chromosomes 3, 4,
5, 8, 10 and 12. The largest stretch of IBD was observed on
chromosome 12 (1942–2599 kb), with high fractions of IBD
between both K2 and K3 isolates. The region encompasses 153
genes including multidrug resistance 2 (MDR2, PVP01_1259100),
and gamete egress and sporozoite traversal (GEST,
PVP01_1258000). Notable genes in other IBD regions include
multidrug resistance 1 (MDR1) on chromosome 10, and dihy-
drofolate synthase/folylpolyglutamase synthase (DHFS-FPGS,
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Fig. 2 Plasmodium vivax population structure in Sabah relative to Thailand and Indonesia. a, b PCoA plots illustrating the genetic differentiation within and
between populations. Principal components 1–4 reﬂect 17.6%, 11.7%, 3% and 1.3% of the variance, respectively. The genetically identical Malaysian K2
isolates are circled in black and the three putatively imported infections are circled in grey; the unlabelled green dots reﬂect the K3 and mixed ancestry
infections which constitute the baseline Sabah population. Aside from the K2 strain, there is clear evidence of divergence among the baseline Sabah
isolates. c An ADMIXTURE bar plot illustrating the population structure within and among populations at K= 4, highlighting the clear distinction between
Thailand, Malaysia and Indonesia, and the marked sub-structure within Malaysia. All plots were generated using genomic data derived from 259 high-
quality samples
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PVP01_1229800) on chromosome 12. Details on the top IBD
regions in Thailand and Indonesia, where a higher threshold of
1% was applied, can be found in Supplementary Fig. 3.
High prevalence of drug resistance mutations in Sabah. To
assess whether the structure within Sabah reﬂected drug selection,
the prevalence of mutations previously associated with clinical or
ex vivo antimalarial resistance2 was investigated (Table 1). Both
the K2 and K3 sub-populations exhibited 100% prevalence of the
MDR1 F1076L and Y976F variants and the dihydropteroate syn-
thase (DHPS) A553G and A383G variants. The prevalence of
reference alleles differed between K2 and K3 at DHPS G626A,
A619T, E618D and E132G (0% in K2 vs. 76–82% in K3, Pearson’s
χ2 test, p= 4.4 × 10−4–4.6 × 10−4) (Supplementary Data 3); the
clinical relevance of these variants is unknown. Although differ-
ences were observed in the prevalence of dihydrofolate reductase
(DHFR-TS) quadruple mutants (0% in K2 vs. 67% in K3,
Pearson’s χ2 test, p= 1.0 × 10−5), overall there was a 100% pre-
valence of one or more mutations in both sub-populations. None
of the Sabah isolates had increased copy number (CN) of MDR1.
The prevalence of non-synonymous variants in orthologues of
genes implicated in drug resistance in P. falciparum was also
investigated (Supplementary Data 3). Plasmepsin IV
(PVP01_1340900) is an orthologue of P. falciparum plasmepsin
II (PF3D7_1408000), in which CN ampliﬁcation has been
associated with piperaquine resistance22,23. The frequency of a
plasmepsin IV I165V variant differed signiﬁcantly between Sabah
(90%) and Thailand (40%, Pearson’s χ2 test, p= 0.0052), but not
Indonesia (89%, Pearson’s χ2 test, p= 1.000). There was no
signiﬁcant difference between the three countries in the
prevalence of variants in pvcrt-o (PVP01_0109300) or kelch-13
(PVP01_1211100), whose P. falciparum orthologues
(PF3D7_0709000 and PF3D7_1343700) are associated with CQ
and artemisinin resistance respectively24,25. Details of the non-
synonymous mutations of the P. vivax orthologues of P.
falciparum multidrug resistance-associated proteins 1 and 2, and
multidrug resistance protein 2 (PVP01_020300, PVP01_1447300
and PVP01_1259100 respectively) are presented in Supplemen-
tary Data 3.
Highly differentiated variants in drug resistance candidates. To
identify potential new modulators of drug resistance, measures of
genetic differentiation (FST) and Rsb-based cross-population
extended haplotype homozygosity were undertaken to detect
gene regions with evidence of selection. The extensive homology
among the K2 isolates obscured signal detection in Sabah; hence,
analysis was undertaken with a single representative of this strain.
A high-level summary of the multi-SNP FST and Rsb signals is
presented in Supplementary Data 4, with detailed results provided
in Supplementary Data 5 and 6, respectively. Seven Sabah-speciﬁc
regions exhibited multiple highly differentiated (FST > 0.8) SNPs
(Fig. 4a, b). In Rsb-based comparisons between Sabah and each of
Thailand and Indonesia, the top 0.5% of SNPs all comprised
regions with extended homozygosity in Sabah (Fig. 5a, b), with 13
and 15 multi-SNP regions identiﬁed, respectively.
Evidence of differential selection was detected with the FST
metric at multiple SNPs in the DHFR-TS and DHPS regions. Both
the FST and Rsb measures found evidence of differential selection
in the chromosome 12 region with high homology in Sabah. Two
non-synonymous MDR2 variants (V43L and A603T) were among
the top 0.5% of SNPs identiﬁed with Rsb analysis in comparisons
against Sabah. The chromosome 5 region with high homology in
Sabah also demonstrated evidence of differential selection
supported by the FST and Rsb measures. In other genomic
regions, putative drug resistance candidates included a putative
drug/metabolite transporter (DMT1, PVP01_1424900) in a region
of chromosome 14 supported by multiple SNPs amongst the top
0.5% of Rsb scores exhibited a V217I variant displaying high
differentiation between Sabah and Thailand (FST= 0.71), and
Thailand and Indonesia (FST= 0.88), but not between Sabah and
Indonesia (FST= 0.02). Also on chromosome 14, a CG2-related
protein (PVP01_1450700) displayed multiple SNPs amongst the
top 0.5% of Rsb scores.
The putative drug resistance-associated signals in the compar-
isons of Thailand vs. Indonesia (Figs. 4c and 5c) have been
described previously11. These include SNPs in DHFR-TS and
DHPS demonstrating high differentiation by FST analysis, and
regions with extended haplotype homozygosity in Thailand
encompassing DHFR-TS and MRP1. A region with extended
haplotype homozygosity in Indonesia was also observed down-
stream of MDR1.
Several genes with functions unrelated to antimalarial drugs
displayed highly differentiated variants, including GEST, which
exhibited two non-synonymous mutations, E68D and K144R,
displaying high differentiation between Sabah and both Thailand
and Indonesia (all FST >0.90), and a Q230L mutation among the
top 0.5% Rsb scores in comparisons of Malaysia to Thailand. In
other regions, the merozoite surface proteins 1 (MSP1) and 5
(MSP5) were notable, exhibiting 15 and 3 variants, respectively,
among the top 0.5% Rsb scores in comparisons of Malaysia to
Thailand and Indonesia.
Signals of extended haplotype homozygosity using the iHS.
Further haplotype-based scans were undertaken using the inte-
grated haplotype score (iHS) measure to identify regions with
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Fig. 3 Neighbour-joining tree illustrating the relatedness between the P.
vivax isolates from Sabah relative to Thailand and Indonesia The plot was
created from genomic data on 259 high-quality infections and illustrates a
rooted tree highlighting the genetically identical K2 cluster in Sabah,
Malaysia. The K3 and mixed infections, which form the baseline Sabah
population, are also annotated. Three putatively imported cases presenting
in Sabah are annotated with black stars. One of the putatively imported
infections (PY0045-C) aligned with the Papua Indonesian isolates,
suggestive of importation from this region, whilst the other two cases
aligned between Papua Indonesia and Sabah (PY0004-C), and close to
Thailand (PY0120-C), presumably reﬂecting importation from regions not
represented by the available sample set
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differential levels of linkage disequilibrium (LD) surrounding the
ancestral (P. cynomolgi) relative to the derived allele. Derived
alleles could be conﬁdently called at only 10,167 loci and, after
ﬁltering out non-informative loci, the homology in Sabah proved
too extensive to permit iHS analysis in this population alone. The
analysis was therefore conducted on the pooled Sabah, Thai and
Indonesian samples. Four regions were supported by multiple
SNPs amongst the top 0.5% of scores (Fig. 5d and Supplementary
Data 4). The ﬁrst region overlaps with a previously described
signal on chromosome 10, potentially reﬂecting selection on
MSP3.226. The second region comprised SNPs in the chromo-
some 12 region with high homology in Sabah. The third
region presents a signal on chromosome 13, possibly driven by
selection on plasmepsin IV. The fourth region overlaps with a
previously described signal on chromosome 14 postulated to
reﬂect selection on an AP2 domain transcription factor
(PVP01_1418100)13. Further details are presented in Supple-
mentary Data 7.
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Fig. 4 Genetic differentiation between Malaysia, Thailand and Indonesia. a–c Manhattan plots illustrating the FST between Malaysia (Sabah), Thailand and
Indonesia. The Sabah population included a single K2 representative and excluded the three imported cases. Horizontal dashed lines illustrate FST= 0.8. A
total of 97 and 76 positions exhibited FST scores ≥0.8 between Sabah and Thailand and Indonesia, respectively; 27 and 19 conferring non-synonymous
changes. Seven multi-SNP regions identiﬁed in comparisons against Sabah are labelled: these regions comprise ≥3 SNPs with FST≥0.8 within 80 kb of one
another. Region 1 encompasses DHFR-TS. Region 2 contains two genes on chromosome 8 with unknown function (PVP01_0834900 and
PVP01_0835000). Region 3 is located on chromosome 12 and includes a nucleoside transporter (NT1) with a highly differentiated L188M mutation between
Sabah and Thailand, but not Sabah and Indonesia. Regions 4 and 5 are located adjacently on chromosome 12, corresponding with the highly homologous
Sabah sequence. The regions contain biologically plausible drug resistance candidates including MDR2 and haeme detoxiﬁcation protein (HDP). Another
notable gene is GEST, implicated in transmission between the parasite and both its Anopheline and human hosts37. Region 6 encompasses DHPS. Region 7 is
located on chromosome 14, encompassing 7 genes but with no clear driver of selection. Region 8 contains several SNPs on chromosome 13 exhibiting
differentiation between Thailand and Indonesia only. The region encompasses the cysteine repeat modular protein 3 (CRMP3). In addition to GEST and
CRMP3, two other genes with roles in host cell invasion or egress displayed highly differentiated variants; CRMP1 and glideosome-associated protein 40
(GAP40). Signatures of selection between southeast Asian and South American P. vivax populations have previously been observed in CRMP126, but this is
the ﬁrst report of selection in GEST and GAP40
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Assessment of the iHS and of the Rsb tests using strictly
monoclonal samples demonstrated no major differences in the
key trends, conﬁrming the accuracy of the results on the low-
complexity samples (Supplementary Fig. 4).
CN ampliﬁcations in Sabah. Investigation of CN variation was
undertaken on 46 Sabah, 104 Thai and 84 Indonesian isolates:
excluding 22 isolates with uneven coverage. Three regions
demonstrated evidence of CN ampliﬁcation in Sabah; a
28S ribosomal RNA gene on chromosome 5 (PVP01_0504500),
duffy-binding protein 1 on chromosome 6 (DBP1,
PVP01_0623800)11,27,28 and an exported Plasmodium protein
with unknown function on chromosome 14 (PVP01_1470400)11
(Table 2 and Supplementary Data 8). The PVP01_0504500 and
PVP01_1470400 ampliﬁcations were highly prevalent in Sabah
(82–96% in K2 and K3), and also demonstrated moderate to high
frequency in Thailand (92 and 49%) and Indonesia (95 and 46%).
Increasingly unstable transmission in Sabah over time. To
explore the epidemiology of P. vivax in Sabah further, genetic
data were obtained on a larger collection of samples using short
tandem repeat (STR) genotyping. A total of 212 independent
PCR-conﬁrmed P. vivax mono-species or mixed-species infec-
tions were successfully genotyped (<50% marker fails), with 187
isolates having complete data. Demographic details of the patients
are summarised in Supplementary Table 1.
Among the 51 genomic samples, 47 could be genotyped
successfully, with 46 having complete data. Consistent with the
genomic data, all 25 K2 infections exhibited the same multi-locus
genotype (MLG38). A further 44 samples carried MLG38,
comprising 69 K2 isolates in total (Fig. 6a). Assessment of the
temporal dynamics of the K2 strain revealed epidemic-like
transmission. K2 was ﬁrst observed in 2013 (29%), rose sharply
in prevalence in 2014 (55%) and persisted into 2015 (83%) up to
the end of the collection period (Fig. 6b).
In addition to K2, several smaller clusters of highly related
infections were observed in Sabah, indicative of broadly unstable
transmission in the region (Fig. 6a). Collectively, the results of
several population genetic measures indicated a state of declining
transmission intensity concurrent with increasing instability.
First, a gradual decline was observed in the percentage of
polyclonal infections, dropping from 50% in 2010 to 8% in 2014
(p= 1.16 × 10−6), suggestive of reduced rates of superinfection
(Supplementary Table 2), and this was associated with a strong,
positive correlation between the annual number of P. vivax cases
and the proportion of polyclonal infections (Pearson’s correla-
tion, r= 0.98, p= 0.004). Second, there was a trend of declining
diversity, as measured by allelic richness (Rs), over the study years
(Supplementary Table 2). Third, investigations of LD revealed
high allelic associations (ISA range 0.167–0.536), reﬂecting high
rates of inbreeding owing to a composite of bottlenecking and
clonal expansions (Supplementary Table 3). On restricting
analysis to unique MLGs, LD remained signiﬁcant in all years,
but the ISA scores dropped between 1.5-fold and 10-fold in each
year, indicative of epidemic-like transmission. The trends in Rs
and LD remained the same when analysis was restricted to low-
complexity infections (Supplementary Tables 2 and 3).
High proportion of outbreak (K2) infections among students.
To characterise the epidemiology surrounding the expansion of
the K2 strain (MLG38), we explored the demographics of indi-
viduals carrying K2 vs. low-frequency strains (Supplementary
Table 4). No signiﬁcant difference was observed in the proportion
of males (62 vs. 73%, Pearson's chi-squared test, p > 0.05) or
median parasite density (4180 vs. 4186 parasites µl−1, Wilcoxon's
rank-sum test, p > 0.05). However, a signiﬁcant difference was
observed in the median age of patients carrying K2 (15 years) vs.
low-frequency MLGs (24 years, p= 0.0137). Occupational details
were available for 182 (97%) of the patients with complete MLGs.
Two categories were investigated; agricultural/foresty-related
occupations and students. A higher proportion of students were
observed among the patients carrying K2 (37%) vs. low-frequency
MLGs (16%, Pearson's chi-squared test, p= 0.012). No signiﬁcant
differences were observed in the proportion of patients with
agricultural/forestry-related occupations (Pearson's chi-squared
test, p > 0.05).
Discussion
Multiple genomic studies have been conducted in the Asia-Paciﬁc
region10,11,13, but none have examined the molecular epide-
miology of P. vivax during the critical transition phase to elim-
ination. Our investigation of the genetic and genomic
epidemiology of P. vivax in Sabah, Malaysia, provides important
insights into the molecular changes taking place in a parasite
population in the late stages of malaria elimination. Our analysis
reveals a highly structured population with high relatedness,
Table 1 Prevalence of variants that have previously been associated with P. vivax drug resistance
Gene Chr. Positions Mutation Drug Sabah
frequency
Sabah K2
frequency
Sabah K3
frequency
Thailand
frequency
Indonesia
frequency
MDR1 10 479,908 F1076L CQ 98% (50/51) 100% (26/26) 100% (17/17) 50% (54/104) 100% (104/104)
(PVP01_1010900) 10 480,207 Y976F CQ, AQ+ SP 94% (48/51) 100% (26/26) 100% (17/17) 13% (14/104) 100% (104/104)
10 Copy number variant 2+ copies MQ 0% (0/49) 0% (0/26) 0% (0/17) 19% (20/104) 0% (0/84)
DHFR-TS 5 1,077,530; 1,077,532 F57L/I Antifolate,
AQ+ SP
96% (46/48) 100% (26/26) 100% (15/15) 91% (88/97) 81% (71/88)
(PVP01_0526600) 5 1,077,533; 1,077,534;
1,077,535
S58R Antifolate,
AQ+ SP
34% (17/50) 0% (0/26) 69% (11/16) 100% (104/104) 99% (97/98)
5 1,077,543 T61M Antifolate,
AQ+ SP
25% (13/51) 0% (0/26) 67% (10/15) 91% (90/99) 81% (71/88)
5 1,077,711 S117N/T Antifolate,
AQ+ SP
25% (12/48) 100% (26/26) 100% (17/17) 100% (102/102) 99% (87/88)
Double
mutant
Antifolate,
AQ+ SP
73% (35/48) 100% (26/26) 33% (5/15) 1% (1/89) 17% (15/87)
Triple
mutant
Antifolate,
AQ+ SP
2% (1/48) 0% (0/26) 0% (0/15) 0% (0/89) 0% (0/87)
Quadruple
mutant
Antifolate,
AQ+ SP
25% (12/48) 0% (0/26) 67% (10/15) 99% (88/89) 82% (71/87)
DHPS 14 1,270,401 A553G Antifolate 92% (46/50) 100% (26/26) 100% (17/17) 98% (98/100) 18% (16/91)
(PVP01_1429500) 14 1,270,911 A383G Antifolate 96% (48/50) 100% (26/26) 100% (17/17) 100% (104/104) 97% (99/102)
Mutation prevalence was calculated with homozygous calls only. Genotype failures were <5% at all markers in all populations
CQ chloroquine, AQ amodiaquine, SP sulfadoxine-pyrimethamine, MQ meﬂoquine
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declining diversity and increased inbreeding demonstrative of
marked interruption to local transmission. A continual ﬂux was
observed in the genetic make-up of the parasite population,
including several small and one large, rapidly emerging clonal
expansion. Whilst some of these changes may have resulted from
demographic or neutral processes, others may reﬂect more con-
cerning adaptive changes as the parasite population is bot-
tlenecked under heavy pressure from antimalarial drugs and
other selective forces.
Antimalarial drug pressure in P. falciparum has been shown to
have an important role in shaping the genetic make-up in
Cambodian isolates29. We postulate that selection may have had a
similar impact on P. vivax in Sabah. Genomic studies have shown
that antimalarial drugs confer some of the strongest selective
pressures on the parasite genome10–13. Intense drug selection is a
highly likely consequence of the ﬁnal stages of elimination, pro-
viding an environment in which only the most drug-resistant
infections survive30. Furthermore, the population structure in low
transmission settings may foster the emergence of multigenic
resistance phenotypes. In highly structured populations where
inbreeding is common, the resistance alleles are likely to be
common and unlikely to be separated during recombination. The
Sabah P. vivax population exhibited a highly structured pattern,
with divergence not just of the K2 strain, but also among the K3
and mixed infections. The extreme divergence in Sabah relative to
the other Asia-Paciﬁc populations mirrors that observed in P.
falciparum in Cambodia as artemisinin-resistant founder popu-
lations emerged29, suggesting that founder populations may
already be emerging in response to selective pressures. However,
additional phenotypic data are needed to conﬁrm this hypothesis
as the extensive divergence in Sabah may also reﬂect extensive
bottlenecking alone.
Until recently, CQ was recommended for treating P. vivax
blood-stage infections in Malaysia. However, the vivax population
Table 2 Summary of copy number variants observed in Sabah
Gene Description Chr. Sabah
frequency
Sabah K2
frequency
Sabah K3
frequency
Thailand
frequency
Indonesia
frequency
PVP01_0504500 28S ribosomal RNA 5 89% (41/46) 96% (25/26) 82% (14/17) 92% (96/104) 95% (80/84)
PVP01_0623800 Duffy-binding protein 1 6 4% (2/46) 0% (0/26) 6% (1/17) 30% (31/104) 6% (5/84)
PVP01_1470400 Plasmodium exported
protein
14 89% (41/46) 96% (25/26) 82% (14/17) 49% (51/104) 46% (39/84)
Twenty-two samples with an excess of CNVs (18+) were excluded from the analysis
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in Sabah has also been exposed to artemisinin, meﬂoquine,
lumefantrine and sulfadoxine plus pyrimethamine, which have
been used to treat co-endemic Plasmodium species. In 2016, the
efﬁcacy of CQ against P. vivax in Sabah was shown to have fallen
below 40%, and antimalarial guidelines were changed to
artemether-lumefantrine for all species of malaria19. Prior to this
date there had been no formal clinical evaluation of CQR in P.
vivax in Malaysia, although a retrospective hospital-based study
from peninsular Malaysia between 1994 and 2010 suggested low
levels of CQR31.
We were able to compare the parasite genomes collected in
Sabah with those collected from western Thailand and Papua,
Indonesia. Previous clinical surveys between 2007 and 2010 have
shown low levels of CQR (<15% recurrence by day 28) in P. vivax
populations on the Thai-Myanmar border32,33. In Papua, Indo-
nesia high-grade CQR (>60% recurrence by day 28) was docu-
mented in 2005 following which antimalarial policy was changed
to DHA-piperaquine21. Over the past 12 years nearly all patients
with uncomplicated malaria, in both the public and private sector,
are treated with DHA-piperaquine, with very little use of CQ34.
The prevalence of CQ resistant P. vivax isolates may therefore
have declined in recent years; however, no clinical data are
available to conﬁrm this.
We observed a high prevalence (95–100%) of polymorphisms
previously associated with drug resistance in P. vivax, including
double, triple and quadruple mutations in DHFR-TS and DHPS
in Sabah. Signals of differential selection reﬂecting different
haplotypic backgrounds were also observed in the DHFR-TS and
DHPS regions in comparisons between Sabah and Thailand and
Indonesia. A high prevalence of MDR1 Y976F and F1076L var-
iants was also observed in Sabah. However, MDR1 appears to be,
at best, a modulator of CQR, with deﬁnitive markers of resistance
to this drug remaining elusive2.
On investigation of polymorphisms previously associated
with drug resistance in P. vivax in K2 vs. K3, we observed
differences in the prevalence of several DHPS and DHFR-TS
alleles, potentially reﬂecting sulfadoxine-pyrimethamine pressure.
The extensive homology in the K2 sub-population did not permit
genome-wide investigations of differential selection and haplo-
type homozygosity to identify any novel selective determinants.
Nonetheless, although the K2 sub-population was notable for its
extreme genetic identity, the extensive divergence across Sabah
was not restricted to this strain. Therefore, rather than limiting
our investigation of drug-related selective pressure to the
K2 strain, we undertook genome-wide tests of selection in the
baseline Sabah population using a single K2 representative.
Several new genes identiﬁed using genome-wide tests of
selection in the current study present plausible molecular deter-
minants of CQR. The MDR2 gene is a biologically plausible
resistance determinant owing to its function as a cellular trans-
porter, and was located on a speciﬁc haplotype background in the
majority of Sabah isolates in a region with evidence of extended
haplotype homozygosity based on iHS analysis, and differential
selection based on FST and Rsb measures. The MDR2 gene also
demonstrated differential selection in Sabah relative to Thailand
and Indonesia at non-synonymous variants supported by both
the FST and Rsb metrics.
The P. vivax CG2-related protein, on chromosome 14, presents
another putative determinant of CQ efﬁcacy. In P. falciparum,
CG2 protein is involved in the uptake and digestion of hae-
moglobin in erythrocytic stage parasites35. Other biologically
plausible genes identifed as potential modulators of resistance to
CQ or other antimalarials on the basis of intragenic supporting
SNPs with evidence of genetic differentiation or extended hap-
lotype homozygosity included plasmepsin IV and drug/metabolite
transporter 1. The plasmepsin IV gene on chromosome 13, which
encodes a hemoglobinase, and exhibited an I165V variant
amongst the top 1% of iHS scores, is intriguing owing to the role
of CN variation in P. falciparum plasmepsin II in piperaquine
resistance22,23.
The candidates identiﬁed add several new genes for con-
sideration in future molecular studies of P. vivax drug resistance,
although these require further investigation and validation with
clinical or ex vivo phenotypes. Whilst we were conservative in our
selection of regions under positive selection, and identiﬁed sig-
natures in previously reported regions, the population structure
in Sabah presents a challenge in this low-endemic setting. Fur-
thermore, comparison with the Indonesian isolates, where high-
grade CQR has been reported previously, may have been con-
founded by the high rate of local transmission36, which may have
rapidly reduced haplotype homozygosity surrounding any drug
resistance alleles in this population.
Selective forces other than antimalarial drug pressure may have
also shaped the genetic structure in Sabah. There was evidence of
differential selection in multiple genes involved in gamete egress
and sporozoite traversal, including GEST. The P. berghei ortho-
logue of GEST has important roles in mediating transmission
between the parasite and both its Anopheline and human hosts37,
and hence certain variants of this gene may inﬂuence transmis-
sion. In addition, there was evidence of extended haplotypes in
Sabah in regions encompassing MSP1 and MSP5, potentially
reﬂecting immune-related pressure.
In addition to selective forces, the genetic dynamics in Sabah
are likely to have been inﬂuenced by demographic factors. Using
STR-based genotyping data, we were able to explore the con-
tribution of several host demographic factors to the expansion of
the K2 strain. The data revealed that students relative to other
occupational groups assessed were more likely to carry K2 alleles
than low-frequency strains. This ﬁnding might reﬂect factors
related to the immune status of this particular age group, who had
a median age of 15 years. Alternatively, it might reﬂect a high-
frequency of K2 transmission events taking place in or around
school, college or home, highlighting occupation as a potentially
important epidemiological link in reactive case detection strate-
gies. However, further investigation of transmission networks is
required with more detailed epidemiological data.
Based on clustering patterns in the genomic data, we were able
to determine putative imported infections, identifying three cases
in Sabah. The K2 strain did not display any evidence of impor-
tation. Rather, the large stretches of homologous sequence
between K2 and other Sabah infections in regions such as chro-
mosome 12 suggests recent common ancestry. However, we
cannot discard the possibility that the K2 lineage derives from a
local recombination event between an isolate from Sabah and an
imported infection, bringing together genetic features that were
highly adaptive to the local environment.
The moderate diversity in the baseline Sabah population sup-
ports the local adaptive potential. Aside from imported infections,
it will be important to determine the contribution of a hidden
reservoir of asymptomatic or subpatent infections in maintaining
local diversity, and whether the genetic structure of these infec-
tions is comparable to the clinical cases. A genetic study of
actively and passively detected P. vivax cases from Timika, Papua
Indonesia, revealed similar genetic diversity between the two
reservoirs, although a higher frequency of polyclonal infections in
the actively detected cases38. However, there are no data available
on the genetic make-up of passively vs. actively detected P. vivax
in low-endemic settings.
Rebound or resurgence of infection remains a great concern for
malaria elimination programs. The continual ﬂux in the genetic
make-up of the Sabah vivax population, rapid expansion of new
strains and high prevalence of known resistance-associated
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determinants highlight the strong adaptive potential in a popu-
lation on the verge of elimination. These ﬁndings have important
implications for other vivax endemic countries striving to achieve
malaria elimination, underlining critical areas for further
research. A stronger foundation for molecular surveillance is
needed, to track the early emergence of adaptive parasites that
will guide appropriate and timely public health interventions.
Methods
Ethics. All samples were collected with written informed consent from patients or
their legal guardians. Ethical approval was provided by the Human Research Ethics
Committee of Northern Territory Department of Health and Families (HREC-
2010-1431, HREC-2012-1815 and HREC-2010-1396), the Medical Research Ethics
Committee, Ministry of Health, Malaysia (NMMR-10-754-6684, NMRR-12-511-
12579), the Mahidol University Faculty of Medical Technology (MUTM 2011-043-
03), the Eijkman Institute Research Ethics Committee (EIREC-47) and the Oxford
Tropical Research Ethics Committee (OXTREC-45-10).
Study site. The focal study site was in Sabah, Malaysia (Supplementary Fig. 1a).
Details on the epidemiology of malaria in Sabah have been published previously17.
Four species of malaria are endemic in the region: P. falciparum, P. vivax, P.
malariae and P. knowlesi. Whilst the incidence of P. vivax and P. falciparum has
declined substantially over the past decade, P. knowlesi cases have risen markedly,
to become the most common cause of malaria (Supplementary Fig. 1b). There is no
signiﬁcant seasonal variation in malaria transmission, with the region experiencing
moderately constant temperature and high humidity throughout the year. Until
2016, the national policy for treating uncomplicated P. vivax infection was CQ plus
primaquine (14-day regimen), but following documentation of high-grade CQR,
ﬁrst-line treatment was changed to artemether-lumefantrine plus primaquine.
Sample details. Details of the genomic samples are presented in Supplementary
Data 1. The Sabah samples were sourced from clinical and epidemiological studies
conducted at the Queen Elizabeth Hospital in Kota Kinabalu, Kudat District
Hospital or Kota Marudu District Hospital between September 2010 and June
201519,39,40. Two to ﬁve millilitres of venous blood was collected from symptomatic
patients with Plasmodium spp.-positive thick blood smears. A 200 µl aliquot of
blood was set aside for PCR-based assays. The remaining aliquot was subject to
leukocyte depletion by cellulose ﬁltration in preparation for whole-genome
sequencing41. DNA extraction was performed using commercial kits (Qiagen).
Plasmodium species was conﬁrmed by PCR, using previously described assays42,43.
For comparative analysis, previously published genomic data were derived from P.
vivax isolates from Thailand and Indonesia11.
Whole-genome sequencing and data analysis. Leukocyte-depleted samples with
≥50 ng DNA comprising <90% human DNA were subject to whole-genome
sequencing, read alignment and variant calling within the framework of a com-
munity study in the Malaria Genomic Epidemiology Network (MalariaGEN)44.
Brieﬂy, sequencing was undertaken on the Illumina GAII or Hi-Seq 2000 platform
at the Wellcome Trust Sanger Institute. Paired-end libraries were prepared
according to the manufacturer’s protocol. Cluster generation and sequencing were
undertaken following the manufacturer’s protocols for generating standard paired-
end 75–150 bp reads. Reads aligning to the human reference genome were removed
before any analyses were undertaken. The remaining reads were aligned against the
P. vivax P01 reference45 using bwa-mem version 0.7.15 with -M parameter46.
Improvements of the bam ﬁles were undertaken using Picard version 2.6.0 tools
CleanSam, FixMateInformation and MarkDuplicates, and GATK version 3.6 base
quality score recalibration. Standard alignment metrics were generated for each
sample using the ﬂagstat utility from samtools version 1.2 and GATK’s Call-
ableLoci version 3.547,48. SNP discovery and genotype calling were undertaken
using methods deﬁned previously for P. vivax ﬁeld isolates11, with data derived
from the MalariaGEN P. vivax Genome Variation Project release 3.0. A set of
532,751 high-quality bi-allelic SNPs with VQSLOD score >3 were derived from an
initial set of 4,084,419 discovered variants. High-quality samples were deﬁned as
those with ≥95% calls at the high-quality SNPs. A set of 527,107 high-quality
typeable SNPs was then derived by excluding SNPs with >5% missing calls in the
high-quality samples. Missing calls were deﬁned as positions with <5 reads. For
haplotype-based analyses, either the major allele (highest read depth) or reference
allele (at positions with equal allele depths) were used to reconstruct haplotypes at
heterozygote positions. Where missing data were not permitted, haplotypes were
reconstructed using information from calls with <5 reads.
For assessment of parasite relatedness, neighbour-joining (NJ) and PCoA were
conducted using a pairwise distance matrix calculated using the R statistical
package. The NJ plot was created using the iTOL software49. Assessment of
population structure was performed using ADMIXTURE version 1.3.0, with the
most likely number of sub-populations (K) determined by the cross-validation
error50. ADMIXTURE was also used to determine the genetic differentiation (FST)
(combined across all SNPs) between the derived sub-populations.
Within-host infection complexity was assessed using the within-sample F
statistic (FWS)51,52, which estimates the ﬁxation of alleles within each infection
relative to the diversity observed in the total population on a scale from 0 to 1.
Previous studies have demonstrated that an FWS ≥0.95 is highly indicative of clonal
infection51,52. The signiﬁcance of differences in the proportion of infections with
FWS ≥0.95 between populations was assessed using Pearson’s χ2 test.
Measures of pairwise IBD were undertaken using hmmIBD with the default
parameters for recombination rate (based on P. falciparum estimates), and
genotyping error rate, and using allele frequencies estimated by the program53. The
pairwise IBD outputs were then determined at 1 kb intervals across the accessible
regions of each chromosome and average fractions of IBD derived for each position
in each population. Differences in the median IBD between populations were
determined using the Wilcoxon's rank-sum test.
Pairwise measures of the genetic differentiation (FST) at individual SNPs were
calculated using Weir and Cockerham’s formula using the R software54, and results
illustrated as Manhattan plots implemented with the qqman package. Analyses of
cross-population haplotype diversity and genetic differentiation were restricted to
high-quality typable SNPs with minor allele frequency >1% across Sabah, Thailand
and Indonesia.
Population-based measures of haplotype diversity were used to scan the genome
for regions under putative positive directional selection55–57. The Rsb measure of
cross-population extended haplotype homozygosity and the iHS were measured
using the R-based rehh package58. For iHS analysis, ancestral alleles were derived
by mapping P. cynomolgi reads59 against the P. vivax P01 reference. Only positions
where P. cynomolgi calls were homozygote and matched either the reference or
alternative P. vivax allele were included in analysis.
Large CN variations (CNVs) were detected using pysamstats (http://github.
com/alimanfoo/pysamstats), which we have previously used and validated in a
study of P. vivax MDR1 CNV60. For each sample, coverage in non-overlapping 300
bp bins was calculated and normalised by dividing by the median coverage across
all bins with the same integer percentage GC content. A hidden Markov model
implemented with the python package sklearn.hmm.GaussianHMM was used to
call individual CNVs, and all variants >3 kb were recorded. Further validation of
CN ampliﬁcations was undertaken using face-away mapping reads27,28.
Aside from the FWS and FST tests, all genomic analyses were undertaken using
the major allele call at heterozygous positions. IBD analysis was undertaken on
monoclonal samples (FWS ≥0.95). The Rsb and iHS tests were undertaken on low-
complexity samples (deﬁned as FWS≥0.6), and additionally assessed with
monoclonal samples (FWS≥0.95). All other genomic analyses were conducted
without FWS ﬁlters.
STR genotyping and data analysis. Genotyping was undertaken at nine STR
markers (Pv3.27, msp1F3, MS1, MS5, MS8, MS10, MS12, MS16 and MS20) using
methods described previously61. The labelled PCR products were sized by dena-
turing capillary electrophoresis on an ABI-3100 Genetic Analyser with GeneScan
LIZ-600 (Applied Biosystems) internal size standards. Genotype calling was
undertaken using VivaxGEN version 1.062. A threshold of 100 relative ﬂuorescence
units was applied for peak detection, and minor alleles were called if they had ≥33%
height of the predominant allele.
The multiplicity of infection (MOI) for a given sample was deﬁned as the
maximum number of alleles observed at any of the nine markers. Population-level
diversity was assessed using allelic richness (Rs)63. In the isolates with complete
genotyping data, MLGs were reconstructed from the predominant alleles for
assessment of the genetic relatedness between sample pairs using (1-ps) as a
measure of genetic distance64. An unrooted neighbour-joining tree was generated
with the R-based ape package65. The MLGs were also used to assess multi-locus
LD. LD was measured using the standardised index of association (IAS), with
signiﬁcance estimates determined using 10,000 random permutations66. Apart
from measures of polyclonality and MOI, only the predominant allele at each locus
in each isolate was included in th analysis67. Rs and LD analyses were conducted on
all infections and additionally in low-complexity samples (maximum 1 multi-allelic
locus) to assess the potential impact of MLG reconstruction errors.
Differences in proportions were examined using Pearson’s χ2 test. Pearson’s
product–moment correlation and Spearman’s rank correlation was used to test
correlations in parametric and non-parametric data, respectively. All tests were
performed using R, and assuming a signiﬁcance threshold of 0.05.
Data availability. The Illumina sequence reads generated on the new P. vivax
samples from Sabah, Malaysia has been deposited in the European Nucleotide
Archive (ENA) under the accession codes listed in Supplementary Table 5A vcf ﬁle
containing the genotyping data used in the study is available on the MalariaGEN
website (https://www.malariagen.net/resource/24). The authors declare that all
other data supporting the ﬁndings of this study are available within the article
and its Supplementary Information ﬁles, or are available from the authors upon
request.
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